Lonza ( (LZAGY) ) has released its Q4 earnings. Here is a breakdown of the information Lonza presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Lonza is a leading global provider of integrated healthcare solutions, specializing in biologics, small molecules, cell and gene technologies, and capsules and health ingredients. They are a prominent player in the contract development and manufacturing organization (CDMO) sector.
In its latest full-year report for 2024, Lonza posted sales of CHF 6.6 billion and a CORE EBITDA of CHF 1.9 billion, maintaining a strong position despite challenging market conditions. The company’s different divisions showed varied performance, with some divisions facing market headwinds while others experienced growth.
Key financial metrics revealed a slight decrease in sales by 2.1% compared to the previous year, while EBIT saw a 9.5% increase. The Small Molecules division showed notable growth with a 9.1% increase in sales, supported by strong demand and strategic portfolio shifts. Conversely, the Capsules & Health Ingredients division faced a 9.2% decline in sales due to customer destocking. The Biologics division saw a minor decline in sales but managed to achieve underlying growth excluding the impact of COVID-related mRNA sales.
Lonza’s management remains optimistic about future prospects, supported by strategic acquisitions such as the Genentech large-scale biologics manufacturing facility. The company plans to maintain its dividend at CHF 4.00 per share, reflecting confidence in its financial stability. Looking ahead, Lonza is poised to adapt to evolving market demands and optimize its business structure to sustain growth.
